Orexo´s digital therapies deliver therapeutic interventions to patients to prevent, manage, or treat a medical disorder or disease. The programs are available for patients in their own privacy 24/7 and can be used in conjunction with their ongoing treatment plans. Its efficacy has been demonstrated in numerous published clinical trials including thousands of patients.

The therapies are developed based on established cognitive behavioral therapy technique which is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem solving. The aim is to provide support and change patterns of thinking or behavior that are behind patients difficulties.

Go to our digital therapeutic's product websites

Digital Therapies
Technical development
Registration
Approved and/or Launched
US
EU
RoW
Deprexis® Depression
Partner: GAIA AG
Vorvida® Alcohol management
Partner: GAIA AG
MODIA® Opioid use disorder
Partner: GAIA AG
 

Instructions for use

Alcohol management

Depression

Opioid use disorder

Clinical evidence

Evaluated in 1 randomized clinical trial, incl. > 600 patients 1

Evaluated in 13 randomized clinical trials, incl. > 2.800 patients 2

Ongoing randomized clinical trial, incl. more than 430 patients

Length of treatment

180 days

90 days

180 days

3 Questions with Dennis Urbaniak, EVP of Digital Therapeutics

Our pipeline of new commercial opportunities was greatly accelerated through new partnerships, such as SoberGrid, Trinity Health, Justmiine, and also with Walgreens, who we signed a collaboration with at the beginning of January 2022. These complementary platforms have created significant new qualified sales opportunities to pull through in 2022.

  • Drive growing, sustainable demand in the areas that we have secured billable product access.
  • Expand the overall number of users and market access for all three DTx therapies.
  • Successfully scale our MODIA® launch that began in late Q4, 2021.
  • Leverage our learnings from 2020–2021 to optimize our investments and improve long term ROI.

I would like Orexo to be seen as the industry leader in tangible DTx commercialization, delivering real world outcomes for patients while also ensuring DTx becomes a significant contributor to Orexo’s revenue growth and profitability.

Orexo´s digital therapeutics are developed by GAIA AG or in collaboration with GAIA AG who has long experience from developing evidence-based digital therapies within multiple therapeuitc areas. All therapies are developed in consultation with psychologists, physicians and patients and are built on techniques related to cognitive behavioral therapy (CBT).  

GAIA: a world leader in digital therapeutics

  • Proven effectiveness in numerous randomized clinical trials with over 7,000 patients
  • More than 12 years of R&D experience, 20+ CE & FDA compliant products
  • Indications - CNS, immunology, oncology

Source and image rights - GAIA AG

1 Jördis M. Zill, Eva Christalle, Björn Meyer, Martin Härter, and Jörg Dirmaier The Effectiveness of an Internet Intervention Aimed at Reducing Alcohol Consumption in Adults: Results of a Randomized Controlled Trial (Vorvida) Dtsch Arztebl Int 2019; 116: 127–33. DOI: 10.3238/arztebl.2019.0127
2 Twomey et al. (2020), Zwerenz et al. (2017), Berger et al. (2018), Beevers et al. (2017), Klein et al. (2016), Meyer et al. (2015), Moritz et al. (2012), Berger et al. (2011), Meyer et al. (2009), Bücker et al. (2018), Fischer et al. (2015), Schröder et al. (2014)